



Carl H. Camp  
President  
Archway Apothecary, LLC  
2190 Manton Drive  
Covington, LA 70433

Re: Docket No. FDA-2019-P-5833

Dear Mr. Camp:

June 2, 2020

I am writing to inform you that the Food and Drug Administration (FDA) has not yet resolved the issues raised in your citizen petition received on December 10, 2019. Your petition requests that the FDA amend the proposed, "List of Bulk Drug Substances That Can Be Used to Compound Drug Products in Accordance with Section 503A of the Federal Food, Drug, and Cosmetic Act," to permit Nicotinamide Adenine Dinucleotide to remain on the 503A list of bulk drug substances for a period of not less than five years.

FDA has been unable to reach a decision on your petition due to the need to address other Agency priorities. This interim response is provided in accordance with FDA regulations on citizen petitions (21 CFR 10.30(e)(2)). We will respond to your petition as soon as possible given the numerous demands on the Agency's resources.

Sincerely,

Carol Bennett -S

Digitally signed by Carol Bennett -S  
DN: c=US, o=U.S. Government, ou=HHS,  
ou=FDA, ou=People, cn=Carol Bennett -S,  
0.9.2342.19200300.100.1.1=2000004958  
Date: 2020.06.02 15:03:47 -04'00'

Carol J. Bennett  
Deputy Director  
Office of Regulatory Policy  
Center for Drug Evaluation and Research